Gilead’s once weekly Yeztugo bid could challenge the old daily pill versus injection divide
Read how Gilead’s once weekly oral Yeztugo filing could reshape HIV prevention, PrEP adherence and long acting therapy competition.
Pharma & Biotech
Pharma & Biotech
Gilead expands its HIV playbook as lenacapavir moves from niche drug to platform strategy
Gilead’s CROI 2026 data highlight lenacapavir’s evolution into a platform for HIV treatment and prevention. Explore what this changes for clinicians and regulators.
Medical Devices & Diagnostics
Why Q Care Plus is blending PrEP, birth control, and sexual health in one telehealth platform
Q Care Plus adds ED, hair loss, and birth control services to its virtual platform. Find out how this reshapes stigma-free access to sexual wellness care.